AUTHORS
Sree Maneesha Sunkara, MBBS, Abirame Gopinath, MBBS2, Amina Akram, MBBS3, Muhammad Yousuf4, Fahad Hassan Gunjial5, Abhishek Avinash Mangaonkar, MBBS6, Attilio Orazi7, Daniel Arber, MD8, Rong He, MD9, Kaaren Reichard, MD10, Animesh Pardanani, PhD, MBBS11, Naseema Gangat, MBBS12, Mrinal M. Patnaik, MD, MBBS13, Dong Chen, MD, PhD14, Ayalew Tefferi, MD15
AFFILIATIONS
1 Mayo Clinic, Rochester, MN, United States
2 Mayo Clinic, Rochester, MN, United States
3 Mayo Clinic, Rochester, MN, United States
4 Mayo Clinic, Rochester, MN, United States
5 Mayo Clinic, Rochester, MN, United States
6 Mayo Clinic, Rochester, MN, United States
7 Texas Tech University, El Paso, United States
8 University of Chicago, Chicago, United States
9 Mayo Clinic, Rochester, MN, United States
10 Mayo Clinic, Rochester, MN, United States
11 Mayo Clinic, Rochester, MN, United States
12 Mayo Clinic, Rochester, MN, United States
13 Mayo Clinic, Rochester, MN, United States
14 Mayo Clinic, Rochester, MN, United States
15 Mayo Clinic, Rochester, MN, United States
ABSTRACT
Background: The International Consensus Classification (ICC) for myeloid neoplasms (MN) considers abnormal monocyte immunophenotype to be supportive of diagnosis of chronic myelomonocytic leukemia (CMML) (Blood 2022. 140:1200). The corresponding supporting criterion in the World Health Organization (WHO-HAEM5) classification system (Leukemia 2022;36:1703) is specified as abnormal monocyte partitioning by peripheral blood flow cytometry defined by the detection of ≥94% classical monocytes. The current retrospective study sought to validate the diagnostic accuracy of the 94% threshold in distinguishing CMML from other causes of monocytosis.
Methods: Morphologic diagnoses were rendered by Mayo Clinic board-certified hematopathologists following the 2022 ICC criteria (Arber et al. Blood 2022. 140:1200), with CLIA-approved NGS testing used to curate mutational data. Monocyte subset analysis was performed by multiparameter flow cytometric immunophenotyping of peripheral blood using the Monocyte Repartition by CD14/CD16 (MONOF) assay, according to validated clinical laboratory protocol. Monocytes were partitioned according to CD14 and CD16 expression into classical (MO1; CD14+/CD16−), intermediate (MO2; CD14 low+/CD16+), and nonclassical (MO3; CD14-/CD16+) subsets. The percentage of each subset was calculated as a proportion of total gated monocytes. The primary analytical endpoint was the proportion of classical monocytes. Consistent with the validated clinical assay, an MO1 fraction ≥94% was considered an abnormal monocyte repartitioning pattern.
Results: A consecutive series of 323 Mayo Clinic patients with suspected CMML underwent monocyte partitioning (median age 73 years; 67% males). Integrated assessment of bone marrow morphology and clinical evaluation allowed subgrouping of the cases into 5 groups: group 1: definitely CMML (N=91; 28%); group 2: morphologically or clinically suspected CMML (N=63; 20%); group 3: other myeloid neoplasms or precursor states (N=84; 26%); group 4: lymphoid or plasma cell neoplasms (N=15; 5%); and group 5: no evidence of myeloid or lymphoid malignancies (N=70; 22%). The corresponding median absolute monocyte count (AMC x 109/L)/monocyte percentages were 1.7/20, 1.1/15, 0.8/11, 0.8/9, 0.9/8. Abnormal karyotype was seen in 18%, 16%, 26%, 17%, and 4%, respectively, and corresponding mutational frequencies were ASXL1 44%, 37%, 23%, 0%, and 0%; TET2 68%, 64%, 33%, 27%, and 7%; and SRSF2 51%, 43%, 23%, 0%, and 3%. The subcategories of other myeloid neoplasms (group 3) were myelodysplastic syndromes (MDS; N=21), myeloproliferative neoplasms (MPN; N=13), acute myeloid leukemia (AML; N=10), MDS/MPN overlap (N=8), CHIP/CCUS (N=9).
Classical monocyte (Mo1) fraction of ≥94% was seen in 64%, 40%, 27%, 13%, and 11% in groups 1, 2, 3, 4, and 5, respectively. The corresponding median (range) values were 95.3 (82.1-99.8), 92.0 (82.1-99.2), 89.8 (81.3-99.5), 88.8 (82.1-96.3), and 88.7 (82.6-97.8). Specificity of MO1 ≥94% in distinguishing group 1 vs. 3 was 73% and group 1 vs. 5 was 89%, with corresponding diagnostic accuracy values of 68% and 75%; the results were similar when analysis was restricted to oligomonocytic (AMC 0.5-<1 x 109/L) presentation with sensitivity/specificity estimates of 67%/77% and diagnostic accuracy of 74%. Specificity of MO1 ≥94% in distinguishing group 2 vs. 3 was 73% and group 2 vs. 5 was 89%, with corresponding diagnostic accuracy values of 59% and 65%.
Distributions of somatic mutations were similar between group 1 (definite CMML) and group 2 (probable CMML) with only a borderline significant difference in TET2MUT frequency (p=0.07). The two groups were therefore combined for mutation comparisons of patients with MO1 fraction of ≥94% (N=83) vs. <94% (N=71); mutational frequencies were significantly different for TET2 (p<0.01; 78% vs. 52%), NRAS (p=0.01; 6% vs. 20%), KRAS (p<0.01; 7% vs. 25%), and PTPN11 (p=0.03; 1% vs. 10%).
Conclusion: A ≥94% MO1 fraction is more likely to be seen in CMML, as opposed to either other myeloid neoplasms or non-clonal monocytosis. However, its diagnostic accuracy in differentiating CMML from other myeloid neoplasms is limited by suboptimal positive/negative predictive values of 72%/65% for definite and 52%/67% probable CMML. Interestingly, in the context of definite or probable CMML, RAS pathway mutations were more likely to be associated with MO1 fraction of <94%; additional studies are needed for confirmation and clarification of relevance.
DISCLOSURES
Sree Maneesha Sunkara, MBBS: No relevant conflicts of interest to declare.